John Libbey Eurotext

Bulletin du Cancer


News about... the proteasome inhibitor PS341 Volume 89, issue 1, Janvier 2002

CNRS-Inserm, Institut de signalisation, Biologie du développement et cancer, parc Valrose, 06108 Nice Cedex 2.

The proteasome degradation system is one of the most efficient proteolytic process in living cells. We will focus here on a new compound, called PS341, which is the first proteasome inhibitor entering clinical phases. First results about its use in multiple myeloma or leukemic cells will be discussed.